Using a long-abandoned class of opioids as their starting point, scientists have discovered an opioid painkiller that doesn't ...

OPEN AND LEANING ON COMMUNITY SUPPORT. KENTUCKYSHOW! IS TAKING ACTION TO BAN A DANGEROUS AND DEADLY DRUG. BROMAZEPAM HAS BEEN DUBBED THE DESIGNER XANAX. THE SYNTHETIC DRUG IS LINKED TO 48 OVERDOSE ...

Struggling with depression or anxiety can feel overwhelming—and deciding whether to start a medication like Effexor adds ...

The U.S. Drug Enforcement Administration this week formally added bromazolam to the federal schedule of controlled substances, following a push from a 22-state coalition that called on the Trump ...

The Food and Drug Administration issued a warning letter to Novo Nordisk — the maker of Ozempic and Wegovy — for failing to report potential side effects in patients who took its blockbuster ...

Novo Nordisk, the pharmaceutical company behind Ozempic, has received a warning letter from the U.S. Food and Drug Administration over issues with its procedures for reporting potential side effects ...

Novo Nordisk NOVO.B-0.87%decrease; red down pointing triangle received a warning from the Food and Drug Administration for failing to report serious suspected side effects in patients who took the ...

Radiotherapy is a key foundation of oncologic treatment that is used across the spectrum of cancer indications. Advances in imaging, treatment planning, and dose delivery have led to increasingly ...

I am currently arranging to get a shingles vaccination. I had shingles at university and still bear the scars, so I really don’t want to risk getting it again. But I also have in mind the fact that ...

It’s worth the weight — loss, that is. Despite their blockbuster popularity, GLP-1 medications come with a handful of side effects, mainly along the lines of gastrointestinal issues like nausea and ...

A massive review of 23 randomized trials found that statins do not cause the vast majority of side effects listed on their labels. Memory problems, depression, sleep issues, weight gain, and many ...